ADVERTISEMENT
Aurobindo Pharma Q4 Review: Well-Placed To Capture Market Opportunities, Says Motilal Oswal, Maintaining Buy
Aurobindo Pharma's stock is trading at an attractive valuation of 16x FY26E EPS of Rs 73/14x FY27E EPS of Rs 83.5, hence Motilal Oswal reiterates Buy.
28 May 2025, 12:42 PM IST 
Aurobindo Pharma exhibited slightly better-than-expected sales/Ebitda (2%/3% beat) for the quarter.
(Representative image. Photo source: Unsplash)
Aurobindo Pharma delivered the highest-ever quarterly Ebitda in Q4 FY25, led by a higher offtake in the US generics segment and steady traction in the EU segment.
